Literature DB >> 26529126

An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial.

Manuela Merli1, Cristina Lucidi1, Vincenza Di Gregorio1, Barbara Lattanzi1, Valerio Giannelli1, Michela Giusto1, Alessio Farcomeni2, Giancarlo Ceccarelli2, Marco Falcone2, Oliviero Riggio1, Mario Venditti2.   

Abstract

UNLABELLED: Early diagnosis and appropriate treatment of infections in cirrhosis are crucial because of their high morbidity and mortality. Multidrug-resistant (MDR) infections are on the increase in health care settings. Health-care-associated (HCA) infections are still frequently treated as community-acquired with a detrimental effect on survival. We aimed to prospectively evaluate in a randomized trial the effectiveness of a broad spectrum antibiotic treatment in patients with cirrhosis with HCA infections. Consecutive patients with cirrhosis hospitalized with HCA infections were enrolled. After culture sampling, patients were promptly randomized to receive a standard or a broad spectrum antibiotic treatment (NCT01820026). The primary endpoint was in-hospital mortality. Efficacy, side effects, and the length of hospitalization were considered. Treatment failure was followed by a change in antibiotic therapy. Ninety-six patients were randomized and 94 were included. The two groups were similar for demographic, clinical, and microbiological characteristics. The prevalence of MDR pathogens was 40% in the standard versus 46% in the broad spectrum group. In-hospital mortality showed a substantial reduction in the broad spectrum versus standard group (6% vs. 25%; P = 0.01). In a post-hoc analysis, reduction of mortality was more evident in patients with sepsis. The broad spectrum showed a lower rate of treatment failure than the standard therapy (18% vs. 51%; P = 0.001). Length of hospitalization was shorter in the broad spectrum (12.3 ± 7 days) versus standard group (18 ± 15 days; P = 0.03). Five patients in each group developed a second infection during hospitalization with a similar prevalence of MDR (50% broad spectrum vs. 60% standard).
CONCLUSIONS: A broad spectrum antibiotic therapy as empirical treatment in HCA infections improves survival in cirrhosis. This treatment was significantly effective, safe, and cost saving.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26529126     DOI: 10.1002/hep.28332

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

Review 1.  Acute on Chronic Liver Failure-What is in a 'Definition'?

Authors:  Anil C Anand; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2016-09-01

Review 2.  Liver - guardian, modifier and target of sepsis.

Authors:  Pavel Strnad; Frank Tacke; Alexander Koch; Christian Trautwein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

3.  Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis.

Authors:  Jasmohan S Bajaj; Jacqueline G OʼLeary; Puneeta Tandon; Florence Wong; Guadalupe Garcia-Tsao; Patrick S Kamath; Scott W Biggins; Jennifer C Lai; Hugo E Vargas; Benedict Maliakkal; Michael B Fallon; Paul J Thuluvath; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Am J Gastroenterol       Date:  2019-07       Impact factor: 10.864

4.  Intestinal colonization with resistant bacteria: a prognostic marker of mortality in decompensated cirrhosis.

Authors:  S Pouriki; G Vrioni; H Sambatakou; A Alexopoulou; L Vasilieva; I Mani; A Tsakris; S P Dourakis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-09-30       Impact factor: 3.267

Review 5.  Current Concepts on Bacterial and Fungal Infections in Cirrhosis.

Authors:  Salvatore Piano; Paolo Angeli
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-10-09

6.  Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections in Patients With Liver Cirrhosis.

Authors:  Shani Feldman; Alessandro Russo; Giancarlo Ceccarelli; Cristian Borrazzo; Chiara Madge; Mario Venditti; Manuela Merli
Journal:  J Clin Exp Hepatol       Date:  2022-04-21

7.  Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis.

Authors:  Jasmohan S Bajaj; Puneeta Tandon; Jacqueline G OʼLeary; Florence Wong; Scott W Biggins; Guadalupe Garcia-Tsao; Patrick S Kamath; Benedict Maliakkal; Michael B Fallon; Jennifer C Lai; Paul J Thuluvath; Hugo E Vargas; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Am J Gastroenterol       Date:  2019-04       Impact factor: 10.864

8.  Reply to: "The Possible Role of Anti-methicillin-resistant Staphylococus Aureus Antimicrobial Agents in Spontaneous Bacterial Peritonitis".

Authors:  Marco Falcone; Alessandro Russo; Manuela Merli; Mario Venditti
Journal:  Infect Dis Rep       Date:  2015-12-22

9.  The role of prophylactic antibiotics in hepatitis B virus-related acute-on-chronic liver failure patients at risk of bacterial infection: a retrospective study.

Authors:  Xiao-Qin Liu; Xue-Yun Zhang; Yue Ying; Jian-Ming Zheng; Jian Sun; Wen-Hong Zhang; Ji-Ming Zhang; Yu-Xian Huang
Journal:  Infect Dis Poverty       Date:  2021-03-31       Impact factor: 4.520

10.  A cost analysis of a broad-spectrum antibiotic therapy in the empirical treatment of health care-associated infections in cirrhotic patients.

Authors:  Cristina Lucidi; Vincenza Di Gregorio; Giancarlo Ceccarelli; Mario Venditti; Oliviero Riggio; Manuela Merli
Journal:  Clinicoecon Outcomes Res       Date:  2017-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.